VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Hormone Receptor-positive Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer

Interventions

DRUG: VS-6766
DRUG: Abemaciclib
DRUG: Fulvestrant

Sponsor

Adrienne G. Waks

Collaborators

[object Object]
[object Object]